Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Sildenafil is a medication commonly used across conditions presenting with acute episodes of vascular-related dysfunction. Its primary therapeutic domains include managing symptoms related to physical discomfort associated with erectile dysfunction (ED) and addressing conditions involving episodic or fluctuating manifestations like pulmonary arterial hypertension (PAH). The medicine provides supportive relief in these scenarios, which contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability.

The medication may assist with easing the overall symptom burden in clinical contexts where acute or unstable symptom patterns are present. This approach is relevant when supportive symptom management is appropriate for conditions where functional stability becomes affected. This medication supports the patient during difficult episodes by easing distress and maintaining functional stability. For PAH, Sildenafil is applied in addressing the condition marked by increased physiological stress in the lungs, while for ED, it helps with managing the symptoms that interfere with daily functioning related to sexual activity.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Новагра? – Official Regulatory Information

Eligibility for Новагра (Sildenafil Citrate) is determined by strict rules outlined in official regulatory documents, primarily based on contraindications and patient-specific health status. The medication is approved for use in adult men for Erectile Dysfunction (ED) and in adult and pediatric patients (ages 1–17) for Pulmonary Arterial Hypertension (PAH).

Absolute Contraindications

Use is strictly prohibited (contraindicated) for patients taking any form of organic nitrates or nitric oxide donors, or the guanylate cyclase stimulator riociguat. It is also contraindicated in individuals with known hypersensitivity to the drug, a history of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), severe hepatic impairment ( Child-Pugh Class C), severe hypotension, or a recent history of stroke or myocardial infarction.

Age and Condition Restrictions

For the ED indication, the medicine is not indicated for individuals under 18 years of age or for women. Older adults (ge 65 years) and patients with severe renal impairment or mild to moderate hepatic impairment should consider a lower starting dose. Use is not recommended in patients with conditions like Pulmonary Veno-Occlusive Disease (PVOD) or certain hereditary degenerative retinal disorders.

Interactions with other medicines and products

This section compiles the official interaction profile of Sildenafil Citrate ( Новагра) based strictly on governmental regulatory documents.

---

Category	Official Regulatory Documentation Statement
Medicinal product categories with documented interactions	Organic Nitrates, Guanylate Cyclase Stimulators, CYP3A4 Inhibitors and Inducers, Alpha-Blockers, and Antihypertensive Agents.
Specific interacting medicines (if explicitly listed)	Ritonavir, Riociguat, Ketoconazole, Erythromycin, Saquinavir, and Rifampicin.
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic Interaction via reduced clearance due to inhibition of Cytochrome P450 3A4 ( CYP3A4) enzymes. Pharmacodynamic Interaction involving additive vasodilatory effects.
Timing-based interaction rules (if applicable)	The risk of symptomatic hypotension with alpha-blockers is documented to be most likely within 4 hours post-dosing.
Population-specific interaction notes (if applicable)	Severe Hepatic and Renal Impairment result in increased Sildenafil plasma levels, which heightens the risk associated with pharmacokinetic interactions.
Interaction-related restrictions	Co-administration with Organic Nitrates and Riociguat is absolutely contraindicated. Co-administration with other PDE5 Inhibitors is not recommended.

---

Official Interaction Statements

• Co-administration with Organic Nitrates (all forms) is absolutely prohibited due to the risk of severe hypotension.
• The strong CYP3A4 inhibitor Ritonavir officially causes an approximate 11-fold increase in Sildenafil systemic exposure ( AUC).
• Co-administration with alpha-blockers is documented to carry a risk of symptomatic hypotension due to additive peripheral vasodilation.
• Ingestion with a high-fat meal is officially documented to result in a delayed rate of absorption of the product.

Connection to the overall interaction profile

Regulatory documents define the interaction structure through two critical mechanisms: Pharmacodynamic Reinforcement (leading to absolute contraindications) and Pharmacokinetic Modulation (identifying key CYP inhibitors and inducers that severely alter plasma exposure). This classification dictates the mandatory restrictions and constraints necessary for the safe use of Sildenafil Citrate as documented in official prescribing information.

How Новагра Works

The mechanism of Новагра (Sildenafil Citrate) is a selective, enzyme-mediated process that amplifies the body’s natural signal for smooth muscle relaxation, directly influencing local vascular tone regulation.

Targeting the PDE5 Enzyme: Molecular Mechanism

The drug's primary action involves the highly selective, competitive inhibition of the Phosphodiesterase type 5 (PDE5) enzyme. PDE5 is the key biological target responsible for hydrolyzing and deactivating the critical cellular messenger cyclic Guanosine Monophosphate (cGMP). By targeting this enzyme, the drug prevents the breakdown of cGMP, leading to its accumulation within the smooth muscle cells.

Signal Amplification and Vasodilation Cascade

This enzyme inhibition operates within the Nitric Oxide (NO)-cGMP signaling pathway. Crucially, the mechanism is conditional: the drug only amplifies the signal and cannot initiate the process. The resultant accumulation of cGMP activates Protein Kinase G, triggering a cascade that ultimately causes the relaxation of the vascular smooth muscle. This leads directly to vasodilation (widening of blood vessels), resulting in increased localized perfusion.

Novagra (Sildenafil Citrate) is used under distinct administration patterns that depend strictly on the approved indication, which defines the therapy as either intermittent or continuous. The medication is predominantly taken via the oral route as a film-coated tablet, available in strengths such as 25 mg, 50 mg, and 100 mg. An oral suspension and a 10 mg intravenous injection are also authorized forms, primarily for use in specific clinical scenarios related to pulmonary arterial hypertension (PAH).

Official Dosing and Frequency Patterns

Indication	Standard Adult Regimen	Frequency & Timing
Erectile Dysfunction (ED)	Initial dose of 50 mg, maximum dose 100 mg.	Taken as needed, maximum once per day.
Pulmonary Arterial Hypertension (PAH)	Standard dose of 20 mg.	Three times a day (TID), spaced 4 to 6 hours apart.

For the ED regimen, the medication is generally taken approximately 1 hour prior to activity. It may be taken with or without food, although consumption with a high-fat meal may lead to a delay in drug absorption. A reduced starting dose of 25 mg is utilized for the ED indication in specific populations, including older adults, or those with severe renal or hepatic impairment. For patients on the continuous PAH regimen, if a scheduled dose is missed, it should be taken as soon as remembered, but a double dose should strictly not be taken to compensate.

Research Evidence / Overview of Studies for Новагра

---

Evidence for use in Erectile Dysfunction (ED)

Research involving Новагра for Erectile Dysfunction (ED) primarily consists of numerous short-term Randomized Controlled Trials (RCTs) that were double-blind and placebo-controlled. These studies included adult males across a wide range of ages who experienced ED due to various causes. The main outcomes monitored were standardized measurements, such as scores on the International Index of Erectile Function (IIEF) and measures related to the patient's reported ability to engage in sexual intercourse attempts.

The findings from these core placebo-controlled studies describe patterns related to functional measurements taken during the study period. Specifically, research reported on changes measured in patient-reported outcomes describing perceived discomfort and functional limitations. While many studies explored this condition, evidence is limited in certain areas, such as a lack of direct trials comparing Sildenafil Citrate against other available PDE5 inhibitors.

---

Evidence for use in Pulmonary Arterial Hypertension (PAH)

For Pulmonary Arterial Hypertension (PAH), the research base includes pivotal short-term (12–16 week) RCTs that were double-blind, placebo-controlled, and dose-ranging. The research focused on outcomes monitoring physiological strain or stress. The primary outcomes measured included functional capacity metrics like the change in the 6-minute walk distance (6MWD) and shifts in the World Health Organization (WHO) Functional Class of the patients.

Across the core adult RCTs, studies report how symptoms evolved in the observed populations based on the functional metrics. The evidence contributes to understanding symptom patterns and the findings indicate a level of reliability across the main adult research. However, the existing research exploring this complex condition provides limited insight into major clinical events, such as mortality or disease progression over long periods.

---

Long-Term Studies and Maintenance Follow-up

While the initial efficacy trials were short-term, subsequent research explored functional maintenance over longer periods. For both conditions, studies observed responses over defined time intervals in open-label extension cohorts, following some patients for up to one to three years. Research provides context but not individual predictions regarding the durability of the observed functional outcomes, and data are still emerging to fully characterize the long-term impact on overall disease progression or stability in PAH patients.

Key Studies & References

1. Study Details | NCT00057759 | Sildenafil in Treating Erectile Dysfunction in Patients With Prostate Cancer (RCT for specific population)

Common questions about Новагра (FAQ)

Q: How quickly can one expect the effects of Новагра to start?

According to official product information, the onset of action for the ED indication is generally expected to occur within 30 to 60 minutes after administration. This expected timing may vary by individual factors and whether the medicine is taken with food.

Q: What is the risk of a serious adverse event or allergic reaction to Новагра?

Allergic reactions, which can appear as a rash or swelling of the eyes, lips, or throat, are reported in patient information as less common. Official regulatory documents state that the medication is classified as absolutely contraindicated in patients with a known hypersensitivity or allergy to the drug.

Q: Does Новагра lose its effectiveness over time?

Studies and official information indicate that the body does not generally build a tolerance to the medicine itself. If the medicine seems less effective, clinical observations suggest this may be due to the progression of the underlying condition or interference from other health or lifestyle factors.

Q: What are the signs that a person should seek immediate medical help after taking Новагра?

Official regulatory safety information identifies an erection lasting more than four hours (priapism) as an event that requires immediate medical attention. Regulatory documents also identify sudden loss of vision or sudden decrease or loss of hearing as events requiring immediate medical attention.

Q: What is the expected duration of action for Новагра?

The elimination half-life of the active ingredient, which is the time it takes for half the drug to leave the body, is typically about 3 to 4 hours. However, some reported effects may be observed for up to 18 hours after the medicine is taken.

Q: Do all users experience side effects when taking Новагра?

No. Official product documentation categorizes adverse effects based on frequency (such as 'Very Common' or 'Common'). The frequency categorization of adverse effects suggests that a large proportion of users may not experience documented side effects.

Q: Is it safe to consume alcohol while Новагра is active in the system?

Regulatory information notes that consuming alcohol may increase the risk of symptoms such as dizziness or low blood pressure. This is due to the medicine's vasodilatory effect (widening of blood vessels) being intensified by alcohol. Therefore, patient safety materials frequently mention the concept of limiting alcohol consumption due to this interaction.

Q: Does having a condition like diabetes affect eligibility for taking Новагра?

Diabetes is listed in official product information as a medical condition that prescribers should be made aware of when discussing use. While it is not an absolute contraindication, having diabetes is noted as a health factor that can be associated with the treated condition.

Q: Does taking Новагра for a long time lead to dependence?

Clinical information indicates that the medicine is not physically addictive, nor is it habit-forming. Therefore, taking Новагра for a long period of time is not associated with developing physical dependence.

Q: Is Новагра considered an aphrodisiac or does it increase desire?

According to the official product information and mechanism of action, the medicine is not considered an aphrodisiac. It requires sexual stimulation to work and does not, by itself, cause or increase sexual arousal or desire.

Q: What happens if someone accidentally takes more Новагра than intended?

Regulatory guidance notes that exceeding the intended amount may result in an increase in common side effects, such as headache, flushing, or dizziness. If this situation occurs, official guidance indicates that medical guidance should be sought.

Q: Why do some individuals find that Новагра does not work for them?

Clinical observations indicate that non-response or reduced efficacy may be linked to the worsening of the underlying condition or related health factors, such as high blood pressure, diabetes, or high cholesterol. Factors like the specific cause of the underlying issue can sometimes influence the expected outcome.

Q: Are there non-prescription products that contain the active ingredient in Новагра?

Regulatory documentation classifies the active ingredient in Новагра (Sildenafil Citrate) as a prescription-only medicine. Therefore, it is not available in non-prescription or over-the-counter (OTC) formulations.

Q: Are there any known drug interactions related to blood thinners and Новагра?

Official safety notes indicate a documented increased risk of bleeding, specifically nosebleed (epistaxis), when the medication is taken concurrently with certain oral blood thinners, such as vitamin K antagonists. This interaction is noted in official safety materials for prescriber awareness.

Q: Do studies suggest Новагра is safe for people with high cholesterol?

High cholesterol is cited in official information as a medical condition that a prescriber is advised to be informed about and is listed as an underlying factor that can affect treatment response. It is noted in clinical observations related to the underlying condition being treated.

Official Storage and Disposal Instructions for Sildenafil

The official labeling for sildenafil tablets (the active ingredient in Novagra) specifies strict conditions for storage and disposal to maintain product integrity and safety.

Sildenafil tablets must be stored at controlled room temperature, generally between 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). The medication must be kept in its original container and protected from moisture.

For safety, it is a mandatory regulatory requirement to store the tablets out of the sight and reach of children at all times.

When disposing of unused or expired product, instructions require following local requirements for pharmaceutical waste. The product must not be disposed of via household trash or wastewater to prevent environmental contamination.